FDA’s ODAC Votes No to Cancer Drugs Copiktra and Pepaxto By PacConAdmin | September 23, 2022 The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted down cancer drugs Copiktra and Pepaxto at its meeting late last week. Source: Drug Industry Daily Posted in Drug Industry Daily